Search hospitals

>

Alabama

>

Birmingham

University of Alabama at Birmingham Cancer Center

Claim this profile

Birmingham, Alabama 35233

Global Leader in Brain Tumor

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Cancer

Conducts research for Ovarian Cancer

663 reported clinical trials

37 medical researchers

Photo of University of Alabama at Birmingham Cancer Center in BirminghamPhoto of University of Alabama at Birmingham Cancer Center in Birmingham

Summary

University of Alabama at Birmingham Cancer Center is a medical facility located in Birmingham, Alabama. This center is recognized for care of Brain Tumor, Breast Cancer, Lung Cancer, Cancer, Ovarian Cancer and other specialties. University of Alabama at Birmingham Cancer Center is involved with conducting 663 clinical trials across 592 conditions. There are 37 research doctors associated with this hospital, such as Victor T. Lin, Rebecca C. Arend, Amitkumar Mehta, MD, and Pankit Vachhani.

Area of expertise

1

Brain Tumor

Global Leader

University of Alabama at Birmingham Cancer Center has run 74 trials for Brain Tumor. Some of their research focus areas include:

Stage IV
IDH positive
1p/19q co-deletion positive
2

Breast Cancer

Global Leader

University of Alabama at Birmingham Cancer Center has run 65 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 negative
HER2 positive

Top PIs

Clinical Trials running at University of Alabama at Birmingham Cancer Center

Ovarian Cancer

Esophageal cancer

Skin Cancer

Cancer

Breast Cancer

Lung Cancer

Bladder Cancer

Cervical Cancer

Breast cancer

Kidney Cancer

Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Neratinib or Neratinib + Palbociclib

for Cancer

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.

Recruiting

1 award

Phase 2

Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Alabama at Birmingham Cancer Center?

Where is University of Alabama at Birmingham Cancer Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Alabama at Birmingham Cancer Center accept?

What awards or recognition has University of Alabama at Birmingham Cancer Center received?